<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03011528</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2015-13 CombinaiR3</org_study_id>
    <nct_id>NCT03011528</nct_id>
  </id_info>
  <brief_title>First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years</brief_title>
  <acronym>CombinaiR3</acronym>
  <official_title>CombinaiR3 - First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ewing's sarcoma and related tumours (ESFT) are rare tumours, with a peak incidence in the&#xD;
      second decade of life. They start most often from bone, and are characterized by a specific&#xD;
      translocation involving the so-called EWS gene. In one patient out of three, the staging&#xD;
      procedures detect metastatic tumours at the diagnosis, most commonly in lungs, bones, and&#xD;
      bone marrow.&#xD;
&#xD;
      ESFT treatment strategy is multidisciplinary, combining primary chemotherapy, a local&#xD;
      treatment, and consolidation chemotherapy.&#xD;
&#xD;
      The primary metastatic dissemination is the most important prognostic factor, as the survival&#xD;
      rate is around 70-75% for localized tumours, in contrast with less than 50% for patients with&#xD;
      primary metastatic disease.&#xD;
&#xD;
      Among primary metastatic patients, bone involvement and / or bone marrow strike markedly the&#xD;
      prognosis of these patients. While the long-term survival of patients with isolated pleural&#xD;
      pulmonary metastases is approximately 50%, whereas it is only from 0 to 25% in patients with&#xD;
      bone marrow involvement.&#xD;
&#xD;
      In 1999, the Intergroup EURO EWING built a new study protocol for patients with Ewing&#xD;
      tumours. For the patients with primary extrapulmonary metastatic Ewing tumours (R3 patients),&#xD;
      the protocol proposed a heavy induction chemotherapy, in order to propose a consolidation&#xD;
      with high dose chemotherapy to a higher rate of patients. The high-dose Busulfan Melphalan&#xD;
      chemotherapy (BuMel) was based on Busulfan (600 mg/m²) and Melphalan (140 mg/m²), with&#xD;
      autologous peripheral blood stem cell (PBSC) support.&#xD;
&#xD;
      Of note, for the full population of patients with metastatic disease, the 3-year EFS rate was&#xD;
      27% (SD 3%), and the OS rate was 34% (SD 4%), with a median follow-up of 3.9 years after&#xD;
      diagnosis, and a median survival time of 1.6 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ewing's sarcoma and related tumours (ESFT) are rare tumours, with a peak incidence in the&#xD;
      second decade of life. They start most often from bone, and are characterized by a specific&#xD;
      translocation involving the so-called EWS gene. The gene rearrangement results in the&#xD;
      production of a transcription factor, in the majority EWS-FLI1 transcription.&#xD;
&#xD;
      In one patient out of three, the staging procedures detect metastatic tumours at the&#xD;
      diagnosis; metastases involve most commonly lungs, bones, and bone marrow.&#xD;
&#xD;
      Therefore, in addition to local imaging, the initial extension assessment of any Ewing tumour&#xD;
      includes at least a chest CT scan, and a bone marrow extensive evaluation, comprising bone&#xD;
      marrow punctures into several different sectors, bone marrow biopsies, and a bone imaging&#xD;
      evaluation. The FDG-PET scan is more sensible than bone scan and conventional imaging as MRI&#xD;
      in detection of bone metastases. It is more and more widely used in the bone metastasis&#xD;
      search in Ewing tumours and seems useful to complement the search of extra-osseous metastases&#xD;
      (outside the lungs), including that of bone marrow metastases. The full-body MRI is still&#xD;
      under evaluation for the disease extension evaluation.&#xD;
&#xD;
      ESFT treatment strategy is multidisciplinary, combining primary chemotherapy, a local&#xD;
      treatment, and consolidation chemotherapy. The local treatment may combine surgery and / or&#xD;
      radiotherapy, according to the tumour site and size, and to the tumour response. ESFT&#xD;
      chemotherapy is based on alkylating agents (ifosfamide and / or cyclophosphamide), etoposide,&#xD;
      anthracyclines, vincristine, and actinomycin.&#xD;
&#xD;
      The primary metastatic dissemination is the most important prognostic factor, as the survival&#xD;
      rate is around 70-75% for localized tumours, in contrast with less than 50% for patients with&#xD;
      primary metastatic disease. Among primary metastatic patients, bone involvement and / or bone&#xD;
      marrow strike markedly the prognosis of these patients. While the long-term survival of&#xD;
      patients with isolated pleural pulmonary metastases is approximately 50%, whereas it is only&#xD;
      from 0 to 25% in patients with bone marrow involvement.&#xD;
&#xD;
      In 1999, the Intergroup EURO EWING built a new study protocol for patients with Ewing&#xD;
      tumours, localized or metastatic and below 50 years of age. For the patients with primary&#xD;
      extrapulmonary metastatic Ewing tumours (R3 patients), the protocol proposed a heavy&#xD;
      induction chemotherapy, in order to propose a consolidation with high dose chemotherapy to a&#xD;
      higher rate of patients. The high-dose BuMel chemotherapy was based on Busulfan (600 mg/m²)&#xD;
      and Melphalan (140 mg/m²), with autologous peripheral blood stem cell (PBSC) support.&#xD;
&#xD;
      The study enrolled 281 patients with primary dissemination and skeletal metastases, with or&#xD;
      without bone marrow involvement and with or without additional pulmonary metastases or&#xD;
      metastases to other sites. In contrast to the distribution in the entire group of patients&#xD;
      with Ewing tumours, the primary site in this subgroup was extremity in only 31% patients,&#xD;
      pelvis/abdomen in 45%, and axial/other in 24% patients. The overall survival at 3 years was&#xD;
      28% (SD 4%) in the group with primary tumour in the abdomen or pelvis, versus 39% (SD 6%) for&#xD;
      each of the two other groups. Of note, for the full population of patients with metastatic&#xD;
      disease, the 3-year EFS rate was 27% (SD 3%), and the OS rate was 34% (SD 4%), with a median&#xD;
      follow-up of 3.9 years after diagnosis, and a median survival time of 1.6 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Actual">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-tumour effect of the treatment strategy assessed by the number of patients event-free survival (EFS) at 18 months</measure>
    <time_frame>18 months after inclusion of the last patient</time_frame>
    <description>EFS is defined as the time from inclusion date to the first documentation of progression, distant disease, second cancer or death (or last news for patients free of event). The event free survival is estimated by Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumour effect of the dose-intensified induction chemotherapy assessed by the response rate of patients</measure>
    <time_frame>week 19-20 = Response Evaluation 2 (RE2)</time_frame>
    <description>Number of patients with complete response (CR) / partial response (PR) eligible for consolidation phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumour effect of the dose-intensified induction chemotherapy assessed by the number of patients eligible for consolidation phase</measure>
    <time_frame>week 19-20 = RE2</time_frame>
    <description>Number of patients eligible for consolidation phase have good response after induction phase :&#xD;
complete remission on primary tumour and on metastatic sites or&#xD;
very good disease response defined by:&#xD;
complete or partial response according to RECIST 1.1 criteria on primary lesion&#xD;
complete or very good partial response (&gt; 90 %) in case of RECIST 1.1 criteria on metastatic sites AND&#xD;
complete metabolic response in case of metastatic visceral and/or bone/bone marrow lesions, or very good partial response according to investigator's judgment AND&#xD;
in case of bone marrow involvement, bone marrow free of disease on at least one biopsy and two punctures at different sites at RE1 (evaluation after 4 cycles VDC-IE), RE2 (evaluation after 2x4 cycles VDC-IE or 4 cycles VDC-IE+4 cycles TEMIRI), or at the latest RE3 evaluation (evaluation after local treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) is assessed by the number of patients still alive at the end of the three years of treatment</measure>
    <time_frame>3 years = Response Evaluation End-Of-Treatment (EOT RE)</time_frame>
    <description>The overall survival (OS) is estimated by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-years event-free survival (EFS) is assessed by the number of patients without any event at the end of treatment phase</measure>
    <time_frame>3 years = EOT RE</time_frame>
    <description>EFS is defined as the time from inclusion date to the first documentation of progression, distant disease, second cancer or death (or last news for patients free of event). The event free survival is estimated by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>week 19-20 = RE2 ; week 27-28 = Response Evaluation 3 (RE3); 3 years = EOT RE</time_frame>
    <description>Number of patients with treatment-related adverse events using the NCI CTCAE version 4.03 to graduate the severity of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment-related toxicities on laboratory data as assessed by CTCAE v4.03 of the different phases of treatment</measure>
    <time_frame>week 19-20 = RE2 ; week 27-28 = RE3; 3 years = EOT RE</time_frame>
    <description>Number of patients with treatment-related toxicities on laboratory data using the NCI CTCAE version 4.03 to graduate the severity of toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18F-FDG PET evaluation efficacy assessed by primary tumour uptake</measure>
    <time_frame>study inclusion, after week 8 (RE1), after week18-19 (if VDC-IE) or week19-20 (if TEMIRI)=RE2, after local treatment ≤week30 (RE3), from week31 (=RE4), 3 years = EOT RE</time_frame>
    <description>Efficacy assessed by primary tumour uptake (Standardized Uptake Value max at 18F-FDG PET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18F-FDG PET evaluation efficacy assessed by metabolic tumour volume (MTV)</measure>
    <time_frame>study inclusion, after week 8 (RE1), after week18-19 (if VDC-IE) or week19-20 (if TEMIRI)=RE2, after local treatment ≤week30 (RE3), from week31 (=RE4), 3 years = EOT RE</time_frame>
    <description>Efficacy assessed by metabolic tumour volume (MTV at 18F-FDG PET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of circulating tumour cells in blood and bone marrow to correlate with patient outcome (EFS). Ancillary study</measure>
    <time_frame>study inclusion, and/or during Procedure=surgery (if done) either after week 19-20=RE2 or after PBSC infusion=RE4</time_frame>
    <description>sample collected : primary tumour and metastatic site (if possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of circulating tumour cells in blood and bone marrow to correlate with patient outcome (EFS). Ancillary study</measure>
    <time_frame>study inclusion, at each evaluation time (RE1=week8 to Response Evaluation before maintenance therapy (RE5=&lt;week38)), every 3 months during 2 years maintenance therapy, at End of Treatment</time_frame>
    <description>sample collected : blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of circulating tumour cells in blood and bone marrow to correlate with patient outcome (EFS). Ancillary study</measure>
    <time_frame>at diagnosis (before treatment), at 1st evaluation time (RE1=wk8 if bone marrow involvement at diagnosis), at RE2=week19-20 (or RE3=&lt;week30), after PBSC infusion=RE4 or RE5=&lt; week38 (if bone marrow involvement at diagnosis), at End of Treatment</time_frame>
    <description>sample collected : bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of transcriptomic profiles between those of primary disease and those of bone marrow metastases to determine if they are the same or not. Ancillary study</measure>
    <time_frame>study inclusion</time_frame>
    <description>Investigation whether the cells from metastatic material harbour a unique transcriptomic signature compared to primary tumour cells : quantification of EWS-ETS transcript and EWS-ETS gene using Polymerase Chain Reaction (PCR) methods to determine the genomic EWS-ETS translocation loci</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Ewing Sarcoma Family of Tumors</condition>
  <arm_group>
    <arm_group_label>VDC - IE x2 &amp; Surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in Arm A receive&#xD;
VDC-IE x2: Intensified induction phase:&#xD;
4 cycles of VDC (Vincristine Doxorubicine Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if &quot;good response&quot; after the 4th treatment, followed by:&#xD;
4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association&#xD;
Consolidation BuMel High dose chemotherapy (Busulfan Melphalan) followed by Peripheral Blood Stem Cell Infusion&#xD;
Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added&#xD;
Maintenance phase&#xD;
1st year : VC (Vincristine Cyclophosphamide) association&#xD;
2nd year : Cyclophosphamide po 25 mg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VDC - IE &amp; TEMIRI &amp; Surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in Arm B receive&#xD;
VDC-IE &amp; TEMIRI: Intensified induction phase:&#xD;
4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if &quot;poor response&quot; after the 4th treatment, followed by:&#xD;
4 cycles of TEMIRI (Temozolomide-Irinotecan) association&#xD;
Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added&#xD;
Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion&#xD;
Maintenance phase&#xD;
1st year : VC (Vincristine Cyclophosphamide) association&#xD;
2nd year : Cyclophosphamide po 25 mg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VDC - IE x2 &amp; Radiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in Arm C receive&#xD;
VDC-IE x2: Intensified induction phase:&#xD;
4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if &quot;good response&quot; after the 4th treatment, followed by:&#xD;
4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association&#xD;
Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion&#xD;
Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.&#xD;
Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion&#xD;
Maintenance phase&#xD;
1st year : VC (Vincristine Cyclophosphamide) association&#xD;
2nd year : Cyclophosphamide po 25 mg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VDC - IE &amp; TEMIRI &amp; Radiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in Arm D receive&#xD;
VDC-IE &amp; TEMIRI: Intensified induction phase:&#xD;
4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if &quot;poor response&quot; after the 4th treatment, followed by:&#xD;
4 cycles of TEMIRI (Temozolomide-Irinotecan) association&#xD;
Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.&#xD;
Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion&#xD;
Maintenance phase&#xD;
1st year : VC (Vincristine Cyclophosphamide) association&#xD;
2nd year : Cyclophosphamide po 25 mg/m²</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VDC-IE x2</intervention_name>
    <description>Week 1, 5, 9 and week 13:&#xD;
Vincristine, IV, D1, 1.5mg/m²&#xD;
Doxorubicine, IV, D1-D2, 37.5mg/m²&#xD;
Cyclophosphamide, IV, D1, 1.2g/m²&#xD;
Week 3, 7, 11 and week 15:&#xD;
Ifosfamide, IV, D15 to D19, 1.8g/m²/d&#xD;
Etoposide, IV, D15 to D19, 100mg/m²/d</description>
    <arm_group_label>VDC - IE x2 &amp; Radiotherapy</arm_group_label>
    <arm_group_label>VDC - IE x2 &amp; Surgery</arm_group_label>
    <other_name>Intensified Induction VDC-IE x2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VDC-IE</intervention_name>
    <description>Week 1 and week 5:&#xD;
Vincristine, IV, D1, 1.5mg/m²&#xD;
Doxorubicine, IV, D1-D2, 37.5mg/m²&#xD;
Cyclophosphamide, IV, D1, 1.2g/m²&#xD;
Week 3, and week 7:&#xD;
Ifosfamide, IV, D15 to D19, 1.8g/m²/d&#xD;
Etoposide, IV, D15 to D19, 100mg/m²/d</description>
    <arm_group_label>VDC - IE &amp; TEMIRI &amp; Radiotherapy</arm_group_label>
    <arm_group_label>VDC - IE &amp; TEMIRI &amp; Surgery</arm_group_label>
    <other_name>Intensified Induction VDC-IE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEMIRI</intervention_name>
    <description>Week 9, 12, 15 and week 18:&#xD;
Temozolomide, PO, D1 to D5, 150mg/m²/d&#xD;
Irinotecan, IV, D1 to D5, 50mg/m²/d</description>
    <arm_group_label>VDC - IE &amp; TEMIRI &amp; Radiotherapy</arm_group_label>
    <arm_group_label>VDC - IE &amp; TEMIRI &amp; Surgery</arm_group_label>
    <other_name>Intensified Induction TEMIRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Consolidation BuMel</intervention_name>
    <description>After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:&#xD;
Busulfan, IV, D-5 to D-2, dosa according to the weight&#xD;
Melphalan, IV, D-1, 140 mg/m²&#xD;
Peripheral Blood Stem Cell infusion:&#xD;
- PBSC infusion, D0, at least 3.10^6 CD34/kg</description>
    <arm_group_label>VDC - IE &amp; TEMIRI &amp; Radiotherapy</arm_group_label>
    <arm_group_label>VDC - IE &amp; TEMIRI &amp; Surgery</arm_group_label>
    <arm_group_label>VDC - IE x2 &amp; Radiotherapy</arm_group_label>
    <arm_group_label>VDC - IE x2 &amp; Surgery</arm_group_label>
    <other_name>High dose Consolidation chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance</intervention_name>
    <description>* 1st year : VC&#xD;
Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)&#xD;
Cyclophosphamide, PO, 25mg/m² continuously</description>
    <arm_group_label>VDC - IE &amp; TEMIRI &amp; Radiotherapy</arm_group_label>
    <arm_group_label>VDC - IE &amp; TEMIRI &amp; Surgery</arm_group_label>
    <arm_group_label>VDC - IE x2 &amp; Radiotherapy</arm_group_label>
    <arm_group_label>VDC - IE x2 &amp; Surgery</arm_group_label>
    <other_name>2 years maintenance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local treatment by surgery</intervention_name>
    <description>Surgical excision of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy. Radiotherapy can be added</description>
    <arm_group_label>VDC - IE &amp; TEMIRI &amp; Surgery</arm_group_label>
    <arm_group_label>VDC - IE x2 &amp; Surgery</arm_group_label>
    <other_name>Surgery of primary tumour/metastatic sites</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Local treatment by radiotherapy</intervention_name>
    <description>Radiotherapy of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy</description>
    <arm_group_label>VDC - IE &amp; TEMIRI &amp; Radiotherapy</arm_group_label>
    <arm_group_label>VDC - IE &amp; TEMIRI &amp; Surgery</arm_group_label>
    <arm_group_label>VDC - IE x2 &amp; Radiotherapy</arm_group_label>
    <arm_group_label>VDC - IE x2 &amp; Surgery</arm_group_label>
    <other_name>Radiotherapy of primary tumour/metastatic sites</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. - Ewing tumour histologically or cytologically confirmed, harboring a specific&#xD;
             transcript, and with extrapulmonary metastases (including nodal extension) - histology&#xD;
             and FISH results must be consistent, specific transcript can be obtained after&#xD;
             inclusions.&#xD;
&#xD;
          2. - Ewing tumour not previously treated.&#xD;
&#xD;
          3. - Age between 2 and 50 years.&#xD;
&#xD;
          4. - Measurable disease by cross sectional imaging (RECIST 1.1) or evaluable disease with&#xD;
             functional metabolic, positron emission tomography scanner (PET SCAN) or other methods&#xD;
             (e.g., cytology/histology).&#xD;
&#xD;
          5. - General status compatible with the study treatments (LANSKY score ≥ 50%, or&#xD;
             Karnofsky ≥ 50%, or Eastern Cooperative Oncology Group (ECOG) ≤ 2).&#xD;
&#xD;
          6. - Adequate bone marrow function (not applicable in case of bone marrow disease).&#xD;
&#xD;
               -  Platelets ≥ 100 x 109 /L&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥ 1 x 109 /L&#xD;
&#xD;
               -  Hemoglobin ≥ 8g /dL.&#xD;
&#xD;
          7. - Adequate liver function :&#xD;
&#xD;
               -  Aspartate Aminotransferase (AST) and Alanine Transferase (ALT) ≤ 5 x Upper Limit&#xD;
                  Normal (ULN)&#xD;
&#xD;
               -  Total Bilirubin ≤ 2 Upper Limit Normal (ULN). If total bilirubin &gt; 2xULN,&#xD;
                  Bilirubin Conjugated Fraction (BCF) ≤ 2 x ULN&#xD;
&#xD;
          8. - No absolute contra-indication of Busulfan-Melphalan if radiotherapy of the primary&#xD;
             tumour is necessary with specific attention to patient with primary spinal tumor.&#xD;
&#xD;
          9. - Adequate cardiac and renal functions:&#xD;
&#xD;
               -  Creatinine &lt; 1.5 of normal for age or clearance &gt; 60 ml/min/1.73 m²;&#xD;
&#xD;
               -  Left Ventricular Ejection Fraction (LVEF) &gt; 50% and/or shortening fraction &gt; 28%.&#xD;
&#xD;
         10. - No underlying disease contra-indicating the study treatments.&#xD;
&#xD;
         11. - Patient likely compliant with the recommended study medical monitoring during and&#xD;
             after treatments.&#xD;
&#xD;
         12. - Patients of childbearing potential must agree to use adequate contraception for the&#xD;
             duration of study treatments and up to 12 months for women and 6 months for men&#xD;
             following completion of therapy.&#xD;
&#xD;
         13. - Females of childbearing potential must have a negative serum β-human chorionic&#xD;
             gonadotropin (HCG) pregnancy test within 10 days prior study inclusion, and/or urine&#xD;
             pregnancy test within 48 hours before the first administration of the study treatment.&#xD;
&#xD;
         14. - Patients covered by a health insurance system.&#xD;
&#xD;
         15. - Patient, or patient's legal representative, informed and having signed the informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. - Age below 2 or greater than 50 years.&#xD;
&#xD;
          2. - Ewing tumour localized, or solely with pleural and/or lung metastases.&#xD;
&#xD;
          3. - Concomitant disease, particularly infectious disease, likely to interfere with&#xD;
             patient's treatment.&#xD;
&#xD;
          4. - History of cancer, according to investigator's judgment.&#xD;
&#xD;
          5. - Life expectancy &lt; 2 months.&#xD;
&#xD;
          6. - Patient already included in another clinical trial with an investigational drug.&#xD;
&#xD;
          7. - Pregnant or breastfeeding patient.&#xD;
&#xD;
          8. - Person deprived of liberty or under guardianship.&#xD;
&#xD;
          9. - Patient likely unable to comply with the study medical monitoring for geographical,&#xD;
             social or psychological reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie LAURENCE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadège CORRADINI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut d'Hématologie et d'Oncologie Pédiatrique</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chr Felix Guyon</name>
      <address>
        <city>La Réunion</city>
        <state>Saint Denis</state>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bordeaux Chu</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LILLE Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LYON Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille Chu</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Montpellier - Hôpital A. de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes Chu</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PARIS Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PARIS Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strasbourg Chu</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulouse Chu</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TOULOUSE Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NANCY Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nancy Chu</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VILLEJUIF Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>December 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>May 16, 2023</last_update_submitted>
  <last_update_submitted_qc>May 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03011528
org study id: IC 2015-13 CombinaiR3
nct id: NCT03011528
lead sponsor: 
collaborator: 
has dmc: Yes
Ewing's sarcoma and related tumours (ESFT) are rare tumours, with a peak incidence in the
      second decade of life. They start most often from bone, and are characterized by a specific
      translocation involving the so-called EWS gene. In one patient out of three, the staging
      procedures detect metastatic tumours at the diagnosis, most commonly in lungs, bones, and
      bone marrow.

      ESFT treatment strategy is multidisciplinary, combining primary chemotherapy, a local
      treatment, and consolidation chemotherapy.

      The primary metastatic dissemination is the most important prognostic factor, as the survival
      rate is around 70-75% for localized tumours, in contrast with less than 50% for patients with
      primary metastatic disease.

      Among primary metastatic patients, bone involvement and / or bone marrow strike markedly the
      prognosis of these patients. While the long-term survival of patients with isolated pleural
      pulmonary metastases is approximately 50%, whereas it is only from 0 to 25% in patients with
      bone marrow involvement.

      In 1999, the Intergroup EURO EWING built a new study protocol for patients with Ewing
      tumours. For the patients with primary extrapulmonary metastatic Ewing tumours (R3 patients),
      the protocol proposed a heavy induction chemotherapy, in order to propose a consolidation
      with high dose chemotherapy to a higher rate of patients. The high-dose Busulfan Melphalan
      chemotherapy (BuMel) was based on Busulfan (600 mg/m²) and Melphalan (140 mg/m²), with
      autologous peripheral blood stem cell (PBSC) support.

      Of note, for the full population of patients with metastatic disease, the 3-year EFS rate was
      27% (SD 3%), and the OS rate was 34% (SD 4%), with a median follow-up of 3.9 years after
      diagnosis, and a median survival time of 1.6 years.
Ewing's sarcoma and related tumours (ESFT) are rare tumours, with a peak incidence in the
      second decade of life. They start most often from bone, and are characterized by a specific
      translocation involving the so-called EWS gene. The gene rearrangement results in the
      production of a transcription factor, in the majority EWS-FLI1 transcription.

      In one patient out of three, the staging procedures detect metastatic tumours at the
      diagnosis; metastases involve most commonly lungs, bones, and bone marrow.

      Therefore, in addition to local imaging, the initial extension assessment of any Ewing tumour
      includes at least a chest CT scan, and a bone marrow extensive evaluation, comprising bone
      marrow punctures into several different sectors, bone marrow biopsies, and a bone imaging
      evaluation. The FDG-PET scan is more sensible than bone scan and conventional imaging as MRI
      in detection of bone metastases. It is more and more widely used in the bone metastasis
      search in Ewing tumours and seems useful to complement the search of extra-osseous metastases
      (outside the lungs), including that of bone marrow metastases. The full-body MRI is still
      under evaluation for the disease extension evaluation.

      ESFT treatment strategy is multidisciplinary, combining primary chemotherapy, a local
      treatment, and consolidation chemotherapy. The local treatment may combine surgery and / or
      radiotherapy, according to the tumour site and size, and to the tumour response. ESFT
      chemotherapy is based on alkylating agents (ifosfamide and / or cyclophosphamide), etoposide,
      anthracyclines, vincristine, and actinomycin.

      The primary metastatic dissemination is the most important prognostic factor, as the survival
      rate is around 70-75% for localized tumours, in contrast with less than 50% for patients with
      primary metastatic disease. Among primary metastatic patients, bone involvement and / or bone
      marrow strike markedly the prognosis of these patients. While the long-term survival of
      patients with isolated pleural pulmonary metastases is approximately 50%, whereas it is only
      from 0 to 25% in patients with bone marrow involvement.

      In 1999, the Intergroup EURO EWING built a new study protocol for patients with Ewing
      tumours, localized or metastatic and below 50 years of age. For the patients with primary
      extrapulmonary metastatic Ewing tumours (R3 patients), the protocol proposed a heavy
      induction chemotherapy, in order to propose a consolidation with high dose chemotherapy to a
      higher rate of patients. The high-dose BuMel chemotherapy was based on Busulfan (600 mg/m²)
      and Melphalan (140 mg/m²), with autologous peripheral blood stem cell (PBSC) support.

      The study enrolled 281 patients with primary dissemination and skeletal metastases, with or
      without bone marrow involvement and with or without additional pulmonary metastases or
      metastases to other sites. In contrast to the distribution in the entire group of patients
      with Ewing tumours, the primary site in this subgroup was extremity in only 31% patients,
      pelvis/abdomen in 45%, and axial/other in 24% patients. The overall survival at 3 years was
      28% (SD 4%) in the group with primary tumour in the abdomen or pelvis, versus 39% (SD 6%) for
      each of the two other groups. Of note, for the full population of patients with metastatic
      disease, the 3-year EFS rate was 27% (SD 3%), and the OS rate was 34% (SD 4%), with a median
      follow-up of 3.9 years after diagnosis, and a median survival time of 1.6 years.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Anti-tumour effect of the treatment strategy assessed by the number of patients event-free survival (EFS) at 18 months
time frame: 18 months after inclusion of the last patient
description: EFS is defined as the time from inclusion date to the first documentation of progression, distant disease, second cancer or death (or last news for patients free of event). The event free survival is estimated by Kaplan-Meier method.
measure: Anti-tumour effect of the dose-intensified induction chemotherapy assessed by the response rate of patients
time frame: week 19-20 = Response Evaluation 2 (RE2)
description: Number of patients with complete response (CR) / partial response (PR) eligible for consolidation phase
measure: Anti-tumour effect of the dose-intensified induction chemotherapy assessed by the number of patients eligible for consolidation phase
time frame: week 19-20 = RE2
description: Number of patients eligible for consolidation phase have good response after induction phase :
complete remission on primary tumour and on metastatic sites or
very good disease response defined by:
complete or partial response according to RECIST 1.1 criteria on primary lesion
complete or very good partial response (> 90 %) in case of RECIST 1.1 criteria on metastatic sites AND
complete metabolic response in case of metastatic visceral and/or bone/bone marrow lesions, or very good partial response according to investigator's judgment AND
in case of bone marrow involvement, bone marrow free of disease on at least one biopsy and two punctures at different sites at RE1 (evaluation after 4 cycles VDC-IE), RE2 (evaluation after 2x4 cycles VDC-IE or 4 cycles VDC-IE+4 cycles TEMIRI), or at the latest RE3 evaluation (evaluation after local treatment).
measure: Overall survival (OS) is assessed by the number of patients still alive at the end of the three years of treatment
time frame: 3 years = Response Evaluation End-Of-Treatment (EOT RE)
description: The overall survival (OS) is estimated by Kaplan-Meier method.
measure: 3-years event-free survival (EFS) is assessed by the number of patients without any event at the end of treatment phase
time frame: 3 years = EOT RE
description: EFS is defined as the time from inclusion date to the first documentation of progression, distant disease, second cancer or death (or last news for patients free of event). The event free survival is estimated by Kaplan-Meier method.
measure: Number of patients with treatment-related adverse events as assessed by CTCAE v4.03
time frame: week 19-20 = RE2 ; week 27-28 = Response Evaluation 3 (RE3); 3 years = EOT RE
description: Number of patients with treatment-related adverse events using the NCI CTCAE version 4.03 to graduate the severity of adverse events
measure: Number of patients with treatment-related toxicities on laboratory data as assessed by CTCAE v4.03 of the different phases of treatment
time frame: week 19-20 = RE2 ; week 27-28 = RE3; 3 years = EOT RE
description: Number of patients with treatment-related toxicities on laboratory data using the NCI CTCAE version 4.03 to graduate the severity of toxicities
measure: 18F-FDG PET evaluation efficacy assessed by primary tumour uptake
time frame: study inclusion, after week 8 (RE1), after week18-19 (if VDC-IE) or week19-20 (if TEMIRI)=RE2, after local treatment ≤week30 (RE3), from week31 (=RE4), 3 years = EOT RE
description: Efficacy assessed by primary tumour uptake (Standardized Uptake Value max at 18F-FDG PET)
measure: 18F-FDG PET evaluation efficacy assessed by metabolic tumour volume (MTV)
time frame: study inclusion, after week 8 (RE1), after week18-19 (if VDC-IE) or week19-20 (if TEMIRI)=RE2, after local treatment ≤week30 (RE3), from week31 (=RE4), 3 years = EOT RE
description: Efficacy assessed by metabolic tumour volume (MTV at 18F-FDG PET)
measure: Percentage of circulating tumour cells in blood and bone marrow to correlate with patient outcome (EFS). Ancillary study
time frame: study inclusion, and/or during Procedure=surgery (if done) either after week 19-20=RE2 or after PBSC infusion=RE4
description: sample collected : primary tumour and metastatic site (if possible)
measure: Percentage of circulating tumour cells in blood and bone marrow to correlate with patient outcome (EFS). Ancillary study
time frame: study inclusion, at each evaluation time (RE1=week8 to Response Evaluation before maintenance therapy (RE5=<week38)), every 3 months during 2 years maintenance therapy, at End of Treatment
description: sample collected : blood
measure: Percentage of circulating tumour cells in blood and bone marrow to correlate with patient outcome (EFS). Ancillary study
time frame: at diagnosis (before treatment), at 1st evaluation time (RE1=wk8 if bone marrow involvement at diagnosis), at RE2=week19-20 (or RE3=<week30), after PBSC infusion=RE4 or RE5=< week38 (if bone marrow involvement at diagnosis), at End of Treatment
description: sample collected : bone marrow
measure: Comparison of transcriptomic profiles between those of primary disease and those of bone marrow metastases to determine if they are the same or not. Ancillary study
time frame: study inclusion
description: Investigation whether the cells from metastatic material harbour a unique transcriptomic signature compared to primary tumour cells : quantification of EWS-ETS transcript and EWS-ETS gene using Polymerase Chain Reaction (PCR) methods to determine the genomic EWS-ETS translocation loci
arm group label: VDC - IE x2 & Surgery
arm group type: Other
description: Patients in Arm A receive
VDC-IE x2: Intensified induction phase:
4 cycles of VDC (Vincristine Doxorubicine Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if "good response" after the 4th treatment, followed by:
4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association
Consolidation BuMel High dose chemotherapy (Busulfan Melphalan) followed by Peripheral Blood Stem Cell Infusion
Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added
Maintenance phase
1st year : VC (Vincristine Cyclophosphamide) association
2nd year : Cyclophosphamide po 25 mg/m²
arm group label: VDC - IE & TEMIRI & Surgery
arm group type: Other
description: Patients in Arm B receive
VDC-IE & TEMIRI: Intensified induction phase:
4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if "poor response" after the 4th treatment, followed by:
4 cycles of TEMIRI (Temozolomide-Irinotecan) association
Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added
Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion
Maintenance phase
1st year : VC (Vincristine Cyclophosphamide) association
2nd year : Cyclophosphamide po 25 mg/m²
arm group label: VDC - IE x2 & Radiotherapy
arm group type: Other
description: Patients in Arm C receive
VDC-IE x2: Intensified induction phase:
4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if "good response" after the 4th treatment, followed by:
4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association
Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion
Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.
Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion
Maintenance phase
1st year : VC (Vincristine Cyclophosphamide) association
2nd year : Cyclophosphamide po 25 mg/m²
arm group label: VDC - IE & TEMIRI & Radiotherapy
arm group type: Other
description: Patients in Arm D receive
VDC-IE & TEMIRI: Intensified induction phase:
4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if "poor response" after the 4th treatment, followed by:
4 cycles of TEMIRI (Temozolomide-Irinotecan) association
Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.
Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion
Maintenance phase
1st year : VC (Vincristine Cyclophosphamide) association
2nd year : Cyclophosphamide po 25 mg/m²
intervention type: Drug
intervention name: VDC-IE x2
description: Week 1, 5, 9 and week 13:
Vincristine, IV, D1, 1.5mg/m²
Doxorubicine, IV, D1-D2, 37.5mg/m²
Cyclophosphamide, IV, D1, 1.2g/m²
Week 3, 7, 11 and week 15:
Ifosfamide, IV, D15 to D19, 1.8g/m²/d
Etoposide, IV, D15 to D19, 100mg/m²/d
arm group label: VDC - IE x2 & Radiotherapy
arm group label: VDC - IE x2 & Surgery
other name: Intensified Induction VDC-IE x2
intervention type: Drug
intervention name: VDC-IE
description: Week 1 and week 5:
Vincristine, IV, D1, 1.5mg/m²
Doxorubicine, IV, D1-D2, 37.5mg/m²
Cyclophosphamide, IV, D1, 1.2g/m²
Week 3, and week 7:
Ifosfamide, IV, D15 to D19, 1.8g/m²/d
Etoposide, IV, D15 to D19, 100mg/m²/d
arm group label: VDC - IE & TEMIRI & Radiotherapy
arm group label: VDC - IE & TEMIRI & Surgery
other name: Intensified Induction VDC-IE
intervention type: Drug
intervention name: TEMIRI
description: Week 9, 12, 15 and week 18:
Temozolomide, PO, D1 to D5, 150mg/m²/d
Irinotecan, IV, D1 to D5, 50mg/m²/d
arm group label: VDC - IE & TEMIRI & Radiotherapy
arm group label: VDC - IE & TEMIRI & Surgery
other name: Intensified Induction TEMIRI
intervention type: Drug
intervention name: Consolidation BuMel
description: After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:
Busulfan, IV, D-5 to D-2, dosa according to the weight
Melphalan, IV, D-1, 140 mg/m²
Peripheral Blood Stem Cell infusion:
- PBSC infusion, D0, at least 3.10^6 CD34/kg
arm group label: VDC - IE & TEMIRI & Radiotherapy
arm group label: VDC - IE & TEMIRI & Surgery
arm group label: VDC - IE x2 & Radiotherapy
arm group label: VDC - IE x2 & Surgery
other name: High dose Consolidation chemotherapy
intervention type: Drug
intervention name: Maintenance
description: * 1st year : VC
Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)
Cyclophosphamide, PO, 25mg/m² continuously
arm group label: VDC - IE & TEMIRI & Radiotherapy
arm group label: VDC - IE & TEMIRI & Surgery
arm group label: VDC - IE x2 & Radiotherapy
arm group label: VDC - IE x2 & Surgery
other name: 2 years maintenance
intervention type: Procedure
intervention name: Local treatment by surgery
description: Surgical excision of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy. Radiotherapy can be added
arm group label: VDC - IE & TEMIRI & Surgery
arm group label: VDC - IE x2 & Surgery
other name: Surgery of primary tumour/metastatic sites
intervention type: Radiation
intervention name: Local treatment by radiotherapy
description: Radiotherapy of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy
arm group label: VDC - IE & TEMIRI & Radiotherapy
arm group label: VDC - IE & TEMIRI & Surgery
arm group label: VDC - IE x2 & Radiotherapy
arm group label: VDC - IE x2 & Surgery
other name: Radiotherapy of primary tumour/metastatic sites
criteria: 
gender: All
minimum age: 2 Years
maximum age: 50 Years
healthy volunteers: No
last name: Valérie LAURENCE, MD
role: Principal Investigator
affiliation: Institut Curie
last name: Nadège CORRADINI, MD
role: Principal Investigator
affiliation: Institut d'Hématologie et d'Oncologie Pédiatrique
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: France
responsible party type: Sponsor
mesh term: Sarcoma, Ewing
sharing ipd: No